Dr. Reddy’s Laboratories site in Visakhapatnam, India, was issued a Form 483 last month, yet shares rose after a more recent audit where zero observations were noted.
Quintiles and IMS Health have merged to form Quintiles IMS Holdings, effectively creating one of the world’s largest healthcare information portfolios.
Nine months since its IPO, a group of shareholders of CRO (contract research organization) INC Research common stock are looking to sell off 8m shares, according to an SEC filing.
CRO Quintiles on Friday announced the pricing of a secondary public offering of 7,000,000 shares of its common stock at a price to the public of $77.85 per share, which is about $1 more per share than what the stock was selling for on Friday.
China-based CDMO (contract development and manufacturing organization) WuXi PharmaTech has raised about $80m for subsidiary SynTheAll Pharmaceutical Co. (STA) via the private placement of 7.16m common shares of STA stock.
Ex-Allergan CEO David Pyott has spoken of his “total war” battling Valeant’s failed hostile takeover, and given advice to other pharmaceutical companies on how to deal with activist shareholders.
Quintiles has completed its previously announced refinancing in which it entered into new senior secured credit facilities totaling $1.95bn, consisting of a $500m revolving credit facility and $1.45bn of term loans.
With WuXi pushing full steam ahead in its bid to go private, one expert says that the company may be envious of a competing CRO -- Hangzhou Tigermed, which is smaller than WuXi but valued at a higher price on the Shenzhen stock exchange.
Between May 2013, when Quintiles went public, and this week, newly public companies’ stocks in the biopharma outsourcing space have all seen their prices rise by more than 35%.
CRO Covance's stockholders voted Wednesday to adopt the previously announced $6.1bn merger agreement providing for the acquisition of Covance by LabCorp at the special meeting of Covance stockholders.
With PRA and INC Research joining Parexel, Quintiles, Covance and Icon in the land of public companies, 2014 was a year in which the top shelf of CROs filled out.
Quintiles has been upgraded to stable by ratings agency Standard & Poor after a second stock offering and the consolidation of debt through a $300m securitisation facility.
AbbVie’s proposed £31bn ($50bn) takeover of Shire is very likely “dead” after the US biopharma's board changed its recommendation and advised shareholders not to back the bid.
European drugmaker Nicox has agreed to acquire all of the outstanding equity of US-based Aciex Therapeutics, an ophthalmic development company, which will also be a boon for ophthalmic CRO Ora.
Parexel has predicted ten per cent year-on-year revenue growth for FY2015 but has been more modest about its operating margins ahead of its Investor Day tomorrow.
With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.
Analysts from rating agency Moody's have upgraded their view of Quintiles, the world’s “largest pharmaceutical service provider,” from stable to positive.
German chemicals giant BASF expects its revised takeover bid for Norwegian omega-3 API manufacturer Pronova Biopharma ASA to be accepted by resistant shareholders.
BASF says revised offer for omega-3 API maker Pronova Biopharma is fair value given recent Greek Government decision to stop reimbursing two key drugs.
Contract services firm Warnex says its analytical and bioanalytical divisions have attracted ‘interest’ from buyers that would exceed its current market cap.
Brooks Laboratories had a torrid first day on the Bombay Stock Exchange (BSE) with high volume trading taking the firm’s share price on a rollercoaster ride of highs and lows.
Japanese drugmaker, Kyowa Hakko Kirin, has further expanded its presence in foreign markets after agreeing a deal to buy Scottish drug firm, ProStrakan.
ShangPharma expects its cGMP production site, due to open in 2011, and biologics services to drive growth as it builds on a 17 per cent increase in revenues in the third quarter.
Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support.
US CRO PPD has sold its biomarker discovery sciences unit to Caprion Proteomics, bucking the trend that has seen many of its sector rivals invest in this part of the contract research market.
US CRO Life Science Research has become a private company with the completion of its acquisition by Lion Holdings, an investment vehicle owner by CEO Andrew Baker.
IMS Health has confirmed it is “exploring strategic alternatives” after speculation this week suggested that the market analysis group had received a number of takeover bids.
Shareholders have filed an $8bn (€5.7bn) lawsuit against Genzyme alleging that the company’s CEO “issued a series of materially false and misleading statements” about its manufacturing problems.
In the latest twist in an increasing bitter takeover battle, the Ontario Superior Court of Justice has rejected JLL’s bid to oust directors elected to the board of Canadian CMO Patheon in April.
Andrew Baker, the chairman and CEO of Life Sciences Research, an East Millstone, New Jersey, contract research organization, has obtained "a definitive agreement" to acquire the firm for $8.50 per share in cash.
Contracting giant Patheon has started legal action to restrict the voting rights of private equity group JLL Holdings, in the latest move of an increasingly acrimonious takeover battle.
